APH.L

Alliance Pharma
Alliance Pharma PLC - Notification of Half Year Results
12th September 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 8584D
Alliance Pharma PLC
12 September 2024
 

12 September 2024

 

 

 

ALLIANCE PHARMA

("Alliance", "Company" or the "Group")

 

Notification of Half Year Results

 

Alliance Pharma plc (AIM: APH), the international healthcare group, will announce its interim results for the six months ended 30 June 2024 on Monday 30 September 2024.

 

A meeting for analysts will be held at 10.00am on the day of the results at Burson Buchanan, 107 Cheapside, London EC2V 6DN. To register attendance at the meeting, analysts should contact alliancepharma@buchanan.uk.com

A live webcast of the analyst meeting will be accessible via the following link: https://stream.buchanan.uk.com/broadcast/66def9f76b479f7c8e789e9a

Following the meeting, a recording of the webcast will be made available at the investor section of Alliance's website, https://www.alliancepharmaceuticals.com/investors

 

For further information:

 

Alliance Pharma plc

+ 44 (0)1249 466966

Cora McCallum, Head of Investor Relations & Corporate Communications

+ 44 (0)1249 705168

ir@allianceph.com




Burson Buchanan

+ 44 (0)20 7466 5000

Mark Court / Sophie Wills


alliancepharma@buchanan.uk.com




Deutsche Numis (Nominated Adviser and Joint Broker)

+ 44 (0)20 7260 1000

Freddie Barnfield / Duncan Monteith / Sher Shah




Investec Bank plc (Joint Broker)

+ 44 (0)20 7597 5970

Patrick Robb / Ben Lawrence / Maria Gomez de Olea


 

 

About Alliance

 

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 290 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORSFSESFELSEDU]]>
TwitterFacebookLinkedIn